---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-004087"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:53:42.010372+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical reports Q3 loss of $0.08/share; XIPERE approval triggers $19M milestones

## Summary
- XIPERE (triamcinolone acetonide) approved by FDA in Oct 2021 for macular edema associated with uveitis; first product for suprachoroidal injection.
- Approval and pre-launch milestones from partners expected to provide $19M non-dilutive funding, extending cash runway into 2023.
- Q3 2021 net loss $4.9M ($0.08 per share) vs $2.4M ($0.05 per share) in Q3 2020; revenue $3.1M vs $3.4M.
- Cash and cash equivalents $25.2M as of Sep 30, 2021.
- Phase 1/2a OASIS trial of CLS-AX (axitinib) in wet AMD completed dosing in Cohort 2; safety data expected by end of 2021.

## SEC filing metadata
- accession: 0000950170-21-004087
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017021004087/0000950170-21-004087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017021004087/clsd-20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-004087
- JSON: https://secwatch.observer/filing/0000950170-21-004087.json
- Plain text: https://secwatch.observer/filing/0000950170-21-004087.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.